Veracyte, Inc. (VCYT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
VCYT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VCYT Revenue Analysis (2014–2025)
As of March 4, 2026, Veracyte, Inc. (VCYT) generated trailing twelve-month (TTM) revenue of $517.1 million, reflecting strong growth of +18.5% year-over-year. The most recent quarter (Q4 2025) recorded $140.6 million in revenue, up 6.6% sequentially.
Looking at the longer-term picture, VCYT's 5-year compound annual growth rate (CAGR) stands at +34.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $517.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows VCYT's business is primarily driven by Testing (95%), Product (3%), and Biopharmaceutical And Other (2%). With over half of revenue concentrated in Testing, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CAI (+144.9% YoY), ADPT (+42.6% YoY), and YDES, VCYT has underperformed the peer group in terms of revenue growth. Compare VCYT vs CAI →
Peer Comparison
Compare VCYT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VCYTCurrent | $517M | +18.5% | +34.5% | 11.2% | |
 CAI | $812M | +144.9% | +14.3% | 5.6% | |
 ADPT | $179M | +42.6% | +16.0% | -90.8% | |
 YDES | $510,360 | - | - | -286.5% | |
 SEER | $14M | +14.5% | +160.6% | -717.7% | |
 IMDX | $2M | +520.9% | - | -3245.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $517.1M | +16.0% | $362.5M | 70.1% | $57.8M | 11.2% |
| 2024 | $445.8M | +23.5% | $298.1M | 66.9% | $16.1M | 3.6% |
| 2023 | $361.1M | +21.8% | $248.1M | 68.7% | $-85,795,000 | -23.8% |
| 2022 | $296.5M | +35.1% | $195.0M | 65.7% | $-41,081,000 | -13.9% |
| 2021 | $219.5M | +86.8% | $145.1M | 66.1% | $-81,903,000 | -37.3% |
| 2020 | $117.5M | -2.4% | $76.0M | 64.7% | $-35,389,000 | -30.1% |
| 2019 | $120.4M | +30.8% | $83.8M | 69.7% | $-15,127,000 | -12.6% |
| 2018 | $92.0M | +27.9% | $58.9M | 64.0% | $-22,233,000 | -24.2% |
| 2017 | $72.0M | +10.6% | $43.8M | 60.8% | $-26,538,000 | -36.9% |
| 2016 | $65.1M | +31.5% | $39.6M | 60.9% | $-28,803,000 | -44.3% |
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VCYT vs AGIO
See how VCYT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VCYT's revenue growth accelerating or slowing?
VCYT revenue is accelerating at +18.5% year-over-year, exceeding the 5-year CAGR of +34.5%. TTM revenue reached $517M. Growth momentum has increased versus prior periods.
What is VCYT's long-term revenue growth rate?
Veracyte, Inc.'s 5-year revenue CAGR of +34.5% reflects the sustained expansion pattern. Current YoY growth of +18.5% is above this long-term average.
How is VCYT's revenue distributed by segment?
VCYT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.